Basic Information
| RNALocate ID: | RLID:01001790 |
| RNA Symbol: | hsa-miR-145-5p |
| Localization: | Mitochondrion |
RNA Information
| RNA Name: | hsa-miR-145 |
| RNA ID: | miRBase:MIMAT0000437 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 21637849 |
| Tissue/Cell Line: | Skeletal muscle myoblasts |
| Method: | ISH|qRT-PCR |
| Description: | List of microRNA significantly detected in the mitochondrial mRNA at three increasing mtRNA inputs (1, 5 and 35 uL). Table S3 List of microRNA significantly detected (Cp<35) in the mitochondrial mRNA at the two highest mtRNA inputs (5 and 35 uL). Data are collected from Table 4 and S3. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001789 | Cytoplasm | Human colon cancer cell line (HCT-116) | 28964256 |
| RLID:01001791 | Nucleus | Myoepithelial cells | 29073169 |
| RLID:11001812 | Exosome | EBV- and KSHV-negative Burkitt lymphoma cell line (Bjab)|EBV-infected lymphoblastoid cell line (LCL)|KSHV-infected lymphoma cell lines (BCBL-1|TY-1) | 27611973 |
| RLID:11001813 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11001814 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11001815 | Exosome | Renal cancer cells | 21670082 |
| RLID:11001816 | Exosome | Breast milk | 22211110 |
| RLID:11001817 | Exosome | Brain tissue | 23382797 |
| RLID:11001818 | Exosome | Plasma | 23663360 |
| RLID:11001819 | Exosome | Serum | 25135963 |
| RLID:11001820 | Exosome | Cerebrospinal fluid | 25420022 |
| RLID:11001821 | Microvesicle | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11005569 | Exosome | Peripheral blood | 32785072 |
| RLID-D:11000365 | Microvesicle | Fibroblasts|Mesenchymal stem cells|Urine | |
| RLID-D:11001178 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-145-5p | Diffuse large b cell lymphoma | MNDR-E-MI-14880 |
| MNDR | hsa-miR-145-5p | Colorectal adenoma | MNDR-E-MI-14881 |
| MNDR | hsa-miR-145-5p | Oral squamous cell carcinoma | MNDR-E-MI-14882 |
| MNDR | hsa-miR-145-5p | Large cell neuroendocrine cancer | MNDR-E-MI-14883 |
| MNDR | hsa-miR-145-5p | Medulloblastoma | MNDR-E-MI-14884 |
| MNDR | hsa-miR-145-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-14885 |
| MNDR | hsa-miR-145-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-14886 |
| MNDR | hsa-miR-145-5p | Lymphoma | MNDR-E-MI-14887 |
| MNDR | hsa-miR-145-5p | Non-hodgkin lymphoma | MNDR-E-MI-14888 |
| MNDR | hsa-miR-145-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-14889 |
| MNDR | hsa-miR-145-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-14890 |
| MNDR | hsa-miR-145-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-14891 |
| MNDR | hsa-miR-145-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-14892 |
| MNDR | hsa-miR-145-5p | Her2-receptor positive breast cancer | MNDR-E-MI-14893 |
| MNDR | hsa-miR-145-5p | Breast cancer luminal | MNDR-E-MI-14894 |
| MNDR | hsa-miR-145-5p | Neurofibromatosis 1 | MNDR-E-MI-14895 |
| MNDR | hsa-miR-145-5p | Dermatomyositis | MNDR-E-MI-14896 |
| MNDR | hsa-miR-145-5p | Agressive prostate cancer | MNDR-E-MI-14897 |
| MNDR | hsa-miR-145-5p | Bone metastasis of prostate cancer | MNDR-E-MI-14898 |
| MNDR | hsa-miR-145-5p | B-cell malignancy | MNDR-E-MI-14899 |
| MNDR | hsa-miR-145-5p | Gastric cancer | MNDR-E-MI-14900 |
| MNDR | hsa-miR-145-5p | Alzheimer disease | MNDR-E-MI-14901 |
| MNDR | hsa-miR-145-5p | Hypertension | MNDR-E-MI-14902 |
| MNDR | hsa-miR-145-5p | Intracranial aneurysm | MNDR-E-MI-14903 |
| MNDR | hsa-miR-145-5p | Bladder cancer | MNDR-E-MI-14904 |
| MNDR | hsa-miR-145-5p | Esophageal carcinoma | MNDR-E-MI-14905 |
| MNDR | hsa-miR-145-5p | Dysautonomia familial | MNDR-E-MI-14906 |
| MNDR | hsa-miR-145-5p | Myotonic dystrophy | MNDR-E-MI-14907 |
| MNDR | hsa-miR-145-5p | Head and neck cancer | MNDR-E-MI-14908 |
| MNDR | hsa-miR-145-5p | Leukemia | MNDR-E-MI-14909 |
| MNDR | hsa-miR-145-5p | Huntington disease | MNDR-E-MI-14910 |
| MNDR | hsa-miR-145-5p | Chorea | MNDR-E-MI-14911 |
| MNDR | hsa-miR-145-5p | Cardiovascular disease | MNDR-E-MI-14912 |
| MNDR | hsa-miR-145-5p | Carotid stenosis | MNDR-E-MI-14913 |
| MNDR | hsa-miR-145-5p | Moyamoya disease | MNDR-E-MI-14914 |
| MNDR | hsa-miR-145-5p | Lung cancer | MNDR-E-MI-14915 |
| MNDR | hsa-miR-145-5p | Endometrial cancer | MNDR-E-MI-14916 |
| MNDR | hsa-miR-145-5p | Down syndrome | MNDR-E-MI-14917 |
| MNDR | hsa-miR-145-5p | Parkinson disease | MNDR-E-MI-14918 |
| MNDR | hsa-miR-145-5p | Colonic adenomas | MNDR-E-MI-14919 |
| MNDR | hsa-miR-145-5p | Basal-like breast cancer | MNDR-E-MI-14920 |
| MNDR | hsa-miR-145-5p | Cancer | MNDR-E-MI-14921 |
| MNDR | hsa-miR-145-5p | Congenital heart disease | MNDR-E-MI-14922 |
| MNDR | hsa-miR-145-5p | Squamous cell carcinoma | MNDR-E-MI-14923 |
| MNDR | hsa-miR-145-5p | Vascular diseases | MNDR-E-MI-14924 |
| MNDR | hsa-miR-145-5p | Thyroid cancer | MNDR-E-MI-14925 |
| MNDR | hsa-miR-145-5p | Pituitary neoplasms | MNDR-E-MI-14926 |
| MNDR | hsa-miR-145-5p | Pancreatic cancer | MNDR-E-MI-14927 |
| MNDR | hsa-miR-145-5p | Melanoma | MNDR-E-MI-14928 |
| MNDR | hsa-miR-145-5p | Lesch-nyhan syndrome | MNDR-E-MI-14929 |
| MNDR | hsa-miR-145-5p | Rectum adenocarcinoma | MNDR-E-MI-14930 |
| MNDR | hsa-miR-145-5p | Nephroblastoma | MNDR-E-MI-14931 |
| MNDR | hsa-miR-145-5p | Colon cancer | MNDR-E-MI-14932 |
| MNDR | hsa-miR-145-5p | Colon adenocarcinoma | MNDR-E-MI-14933 |
| MNDR | hsa-miR-145-5p | Multiple sclerosis | MNDR-E-MI-14934 |
| MNDR | hsa-miR-145-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-14935 |
| MNDR | hsa-miR-145-5p | Acromegaly | MNDR-E-MI-14936 |
| MNDR | hsa-miR-145-5p | Prostate adenocarcinoma | MNDR-E-MI-14937 |
| MNDR | hsa-miR-145-5p | Kidney cancer | MNDR-E-MI-14938 |
| MNDR | hsa-miR-145-5p | Endometrial carcinoma | MNDR-E-MI-14939 |
| MNDR | hsa-miR-145-5p | Carcinoma ductal breast | MNDR-E-MI-14940 |
| MNDR | hsa-miR-145-5p | Glioblastoma | MNDR-E-MI-14941 |
| MNDR | hsa-miR-145-5p | Glioma | MNDR-E-MI-14942 |
| MNDR | hsa-miR-145-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-14943 |
| MNDR | hsa-miR-145-5p | Central nervous system lymphoma | MNDR-E-MI-14944 |
| MNDR | hsa-miR-145-5p | Chordoma | MNDR-E-MI-14945 |
| MNDR | hsa-miR-145-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-14946 |
| MNDR | hsa-miR-145-5p | Osteosarcoma | MNDR-E-MI-14947 |
| MNDR | hsa-miR-145-5p | Ewing sarcoma | MNDR-E-MI-14948 |
| MNDR | hsa-miR-145-5p | Liposarcoma | MNDR-E-MI-14949 |
| MNDR | hsa-miR-145-5p | Coronary artery disease | MNDR-E-MI-14950 |
| MNDR | hsa-miR-145-5p | Carotid artery thrombosis | MNDR-E-MI-14951 |
| MNDR | hsa-miR-145-5p | Inclusion body myositis | MNDR-E-MI-14952 |
| MNDR | hsa-miR-145-5p | Breast carcinoma | MNDR-E-MI-14953 |
| MNDR | hsa-miR-145-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-14954 |
| MNDR | hsa-miR-145-5p | Meningioma | MNDR-E-MI-14955 |
| MNDR | hsa-miR-145-5p | Liver cancer | MNDR-E-MI-14956 |
| MNDR | hsa-miR-145-5p | Uterine cancer | MNDR-E-MI-14957 |
| MNDR | hsa-miR-145-5p | Gastric adenocarcinoma | MNDR-E-MI-14958 |
| MNDR | hsa-miR-145-5p | Cervical squamous cell carcinoma | MNDR-E-MI-14959 |
| MNDR | hsa-miR-145-5p | Pituitary adenoma | MNDR-E-MI-14960 |
| MNDR | hsa-miR-145-5p | Lung squamous cell carcinoma | MNDR-E-MI-14961 |
| MNDR | hsa-miR-145-5p | Carcinoma lung non-small-cell | MNDR-E-MI-14962 |
| MNDR | hsa-miR-145-5p | Lung adenocarcinoma | MNDR-E-MI-14963 |
| MNDR | hsa-miR-145-5p | Adrenocortical carcinoma | MNDR-E-MI-14964 |
| MNDR | hsa-miR-145-5p | Thyroid carcinoma | MNDR-E-MI-14965 |
| MNDR | hsa-miR-145-5p | Ovarian carcinoma | MNDR-E-MI-14966 |
| MNDR | hsa-miR-145-5p | Bladder urothelial carcinoma | MNDR-E-MI-14967 |
| MNDR | hsa-miR-145-5p | Pancreatic adenocarcinoma | MNDR-E-MI-14968 |
| MNDR | hsa-miR-145-5p | Liver disease | MNDR-E-MI-14969 |
| MNDR | hsa-miR-145-5p | Skin cancer | MNDR-E-MI-14970 |
| MNDR | hsa-miR-145-5p | Intrastent restenosis | MNDR-E-MI-14971 |
| MNDR | hsa-miR-145-5p | Cervical cancer | MNDR-E-MI-14972 |
| MNDR | hsa-miR-145-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-14973 |
| MNDR | hsa-miR-145-5p | Carcinoma renal cell | MNDR-E-MI-14974 |
| MNDR | hsa-miR-145-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-14975 |
| MNDR | hsa-miR-145-5p | Clear cell renal cell carcinoma | MNDR-E-MI-14976 |
| MNDR | hsa-miR-145-5p | Large cell carcinoma | MNDR-E-MI-14977 |
| MNDR | hsa-miR-145-5p | Biliary tract cancer | MNDR-E-MI-14978 |
| MNDR | hsa-miR-145-5p | Adenocarcinoma of esophagus | MNDR-E-MI-14979 |
| MNDR | hsa-miR-145-5p | Cholangiocarcinoma | MNDR-E-MI-14980 |
| MNDR | hsa-miR-145-5p | Esophageal cancer | MNDR-E-MI-14981 |
| MNDR | hsa-miR-145-5p | Oncocytoma | MNDR-E-MI-14982 |
| MNDR | hsa-miR-145-5p | Lung small cell carcinoma | MNDR-E-MI-14983 |
| MNDR | hsa-miR-145-5p | Encephalopathy bovine spongiform | MNDR-E-MI-14984 |
| MNDR | hsa-miR-145-5p | Synovial sarcoma | MNDR-E-MI-14985 |
| MNDR | hsa-miR-145-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-14986 |
| MNDR | hsa-miR-145-5p | Testicular germ cell cancer | MNDR-E-MI-14987 |
| MNDR | hsa-miR-145-5p | Heart failure | MNDR-E-MI-14988 |
| MNDR | hsa-miR-145-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-14989 |
| MNDR | hsa-miR-145-5p | Fibromyalgia | MNDR-E-MI-14990 |
| MNDR | hsa-miR-145-5p | Encephalomyelitis | MNDR-E-MI-14991 |
| MNDR | hsa-miR-145-5p | Pulmonary arterial hypertension | MNDR-E-MI-14992 |
| MNDR | hsa-miR-145-5p | Adenoma | MNDR-E-MI-14993 |
| MNDR | hsa-miR-145-5p | Breast invasive carcinoma | MNDR-E-MI-14994 |
| MNDR | hsa-miR-145-5p | Hepatocellular carcinoma | MNDR-E-MI-14995 |
| MNDR | hsa-miR-145-5p | Embryonal cancer | MNDR-E-MI-14996 |
| MNDR | hsa-miR-145-5p | B-cell non-hodgkin lymphoma | MNDR-E-MI-14997 |
| MNDR | hsa-miR-145-5p | Rheumatoid arthritis | MNDR-E-MI-14998 |
| MNDR | hsa-miR-145-5p | Chronic kidney disease | MNDR-E-MI-14999 |
| MNDR | hsa-miR-145-5p | Barrett's adenocarcinoma | MNDR-E-MI-15000 |
| MNDR | hsa-miR-145-5p | Hodgkin disease | MNDR-E-MI-15001 |
| MNDR | hsa-miR-145-5p | Burkitt lymphoma | MNDR-E-MI-15002 |
| MNDR | hsa-miR-145-5p | Dementia vascular | MNDR-E-MI-15003 |
| MNDR | hsa-miR-145-5p | Acute myelocytic leukemia | MNDR-E-MI-15004 |
| MNDR | hsa-miR-145-5p | Colorectal cancer | MNDR-E-MI-15005 |
| MNDR | hsa-miR-145-5p | Acute myocardial infarction | MNDR-E-MI-15006 |
| MNDR | hsa-miR-145-5p | Multiple myeloma | MNDR-E-MI-15007 |
| MNDR | hsa-miR-145-5p | Ovarian epithelial cancer | MNDR-E-MI-15008 |
| MNDR | hsa-miR-145-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-15009 |
| MNDR | hsa-miR-145-5p | Uterine cervical neoplasms | MNDR-E-MI-15010 |
| MNDR | hsa-miR-145-5p | Nasopharyngeal cancer | MNDR-E-MI-15011 |
| MNDR | hsa-miR-145-5p | Prostatic neoplasms | MNDR-E-MI-15012 |
| MNDR | hsa-miR-145-5p | Sleep deprivation | MNDR-E-MI-15013 |
| MNDR | hsa-miR-145-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-15014 |
| MNDR | hsa-miR-145-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-15015 |
| MNDR | hsa-miR-145-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-15016 |
| MNDR | hsa-miR-145-5p | Pituitary acth hypersecretion | MNDR-E-MI-15017 |
| MNDR | hsa-miR-145-5p | Stroke lacunar | MNDR-E-MI-15018 |
| MNDR | hsa-miR-145-5p | Barrett's carcinogenesis | MNDR-E-MI-15019 |
| MNDR | hsa-miR-145-5p | Breast cancer her3+ negative | MNDR-E-MI-15020 |
| MNDR | hsa-miR-145-5p | Duke B | MNDR-E-MI-15021 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCC1 | Homo sapiens | RR00023260 |
TOP